Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769057 | 0.89 | ADRA1A (0.67) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL769253 | 0.84 | ADRA1A (0.67) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL769211 | 0.84 | ADRA1A (0.67) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL769130 | 0.83 | ADRA1A (0.62) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10751224 | 0.83 | CYP2D6 (0.67) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10751218 | 0.82 | CYP2D6 (0.63) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL34760 | 0.80 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL29603648 | 0.80 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL30292036 | 0.80 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL4628345 | 0.79 | ADRA1A (0.60) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | claimed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ADRA1A 188/4885ADRA2A 102/4885CYP2D6 425/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ADRA1A 203/4885ADRA2A 106/4885CYP2D6 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.